EntryPoint Capital’s Fulgent Genetics FLGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$575K Buy
27,999
+12,254
+78% +$208K 0.14% 270
2026
Q1
$250K Buy
15,745
+8,106
+106% +$176K 0.07% 545
2025
Q4
$201K Sell
7,639
-1,693
-18% -$43.9K 0.08% 555
2025
Q3
$211K Buy
+9,332
New +$192K 0.08% 533
2025
Q1
Sell
-20,771
Closed -$384K 761
2024
Q4
$384K Buy
20,771
+9,556
+85% +$187K 0.16% 223
2024
Q3
$244K Sell
11,215
-7,075
-39% -$158K 0.14% 352
2024
Q2
$359K Buy
18,290
+2,668
+17% +$55.7K 0.17% 115
2024
Q1
$339K Buy
15,622
+15,519
+15,067% +$385K 0.3% 12
2023
Q4
$2.98K Buy
+103
New +$2.76K ﹤0.01% 1255

Other funds holding FLGT

EntryPoint Capital's FLGT Position: Q2 2026 in Review

EntryPoint Capital increased its Fulgent Genetics (FLGT) stake by 78% in Q2 2026, buying an estimated $208K and bringing the position to 27,999 shares worth $575K. The position accounts for 0.14% of the portfolio, ranked #270.

EntryPoint Capital first reported a position in FLGT in Q4 2023 and has held it in 9 quarters since. 142 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • EntryPoint Capital held 27,999 shares of Fulgent Genetics worth $575K as of Q2 2026.
  • EntryPoint Capital bought 12,254 Fulgent Genetics shares in Q2 2026, an estimated $208K.
  • Fulgent Genetics made up 0.14% of EntryPoint Capital's portfolio in Q2 2026, its #270 holding.
  • EntryPoint Capital first reported a position in Fulgent Genetics in Q4 2023 and has held it in 9 quarters since.
  • 142 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.